Table 1.
Baseline Characteristics
| Variables | Daily Trial | Nocturnal Trial | |||
|---|---|---|---|---|---|
|
3× weekly (N=120) |
6× weekly (N=125) |
3× weekly (N=42) |
6× weekly (N=45) |
||
| Age (years) | 52.0 ± 14.1 | 48.9 ± 13.6 | 54.0 ± 12.9 | 51.7 ± 14.4 | |
| Male | 73 (60.8%) | 78 (62.4) | 28 (66.7) | 29 (64.4) | |
| Race | |||||
| Black | 53 (44.2%) | 49 (39.2%) | 11 (26.2%) | 12 (26.7% | |
| White | 46 (38.3%) | 43 (34.4%) | 21 (50.0%) | 27 (60.0%) | |
| Native American, Aboriginal Canadian, Alaskan Native | 4 (3.3%) | 4 (3.2%) | 2 (4.8%) | 1 (2.2% | |
| Asian | 5 (4.2%) | 11 (8.8%) | 7 (16.7%) | 5 (11.1%) | |
| Native Hawaiian or other Pacific Islander | 3 (2.5%) | 1 (0.8%) | 0 (0%) | 0 (0%) | |
| Other/Mixed/Unknown | 9 (7.5%) | 17 (13.6%) | 1 (2.4%) | 0 (0%) | |
| Hispanic/Latino Ethnicity | 31 (26%) | 38 (30%) | 0 (0%) | 0 (0%) | |
| Diabetes | 50 (41.7%) | 50 (40.0%) | 18 (42.9%) | 19 (42.2%) | |
| Hypertension1 | 111 (92.5%) | 117 (93.6%) | 39 (92.9%) | 41 (91.1%) | |
| Coronary artery disease | 16 (13.3%) | 11 (8.8%) | 4 (9.5%) | 5 (11.1%) | |
| Congestive heart failure | 24 (20.0%) | 25 (20.0%) | 7 (16.7%) | 5 (11.1%) | |
| Atrial fibrillation | 9 (7.5%) | 5 (4.0%) | 0 (0.0%) | 6 (13.3%) | |
| Peripheral arterial disease | 10 (8.33%) | 15 (12.0%) | 7 (16.7%) | 8 (17.8%) | |
| Stroke | 9 (7.5%) | 9 (7.2%) | 1 (2.4%) | 1 (2.2%) | |
| COPD | 5 (4.2%) | 6 (4.8%) | 2 (4.8%) | 2 (4.4%) | |
| Body Mass Index (kg/m2) | 27.6 ± 6.8 | 27.5 ± 6.6 | 28.4 ± 7.6 | 29.8 ± 8.3 | |
| ESRD vintage (years) | |||||
| <2 (%) | 38.2 | 29.6 | 71.4 | 62.2 | |
| 2–5 (%) | 35.0 | 27.2 | 11.9 | 17.8 | |
| >5 (%) | 35.8 | 43.2 | 16.7 | 20.0 | |
| Residual urinary volume (L/day) | 0 (0, 0.54) | 0 (0, 0.60) | 0.54 (0, 1.25) | 0.40 (0, 1.33) | |
| Interdialytic weight gain (kg) | |||||
| Per session | 3.12 ± 0.93 | 3.12 ± 0.99 | 2.44 ± 1.47 | 2.27 ± 1.35 | |
| Per week | 9.22 ± 2.96 | 9.17 ± 3.00 | 7.16 ± 4.54 | 6.63 ± 3.60 | |
| Haemoglobin (g/dL) | 12.0 ± 1.2 | 11.9 ± 1.3 | 11.9 ± 1.1 | 11.6 ± 1.1 | |
| Serum sodium (mmol/L) | 138 ± 3 | 138 ± 3 | 139 ± 3 | 138 ± 3 | |
| Dialysate sodium (mmol/L) | 141 ± 3 | 139 ± 2 | 140 ± 2 | 140 ± 2 | |
| Medications use | |||||
| ESA | 111 (92.5%) | 117 (93.6%) | 37 (88.1%) | 38 (84.4%) | |
| Antihypertensives | 105 (87.5%) | 109 (87.2%) | 35 (83.3%) | 38 (84.4%) | |
| ACEI | 38 (31.7%) | 42 (33.6%) | 12 (28.6%) | 7 (15.6%) | |
| ARB | 25 (20.8%) | 30 (24.0%) | 3 (7.1%) | 9 (20.0%) | |
| Dihydropyridine CCB | 53 (44.2%) | 62 (49.6%) | 15 (35.7%) | 18 (40.0%) | |
| Non-Dihydropyridine CCB | 6 (5.0%) | 6 (4.8%) | 3 (7.1%) | 2 (4.4%) | |
| Beta blockers | 77 (64.2%) | 70 (56.0%) | 21 (50.0%) | 30 (66.7%) | |
| Peripheral alpha blockers | 4 (3.3%) | 1 (0.8%) | 4 (9.2%) | 2 (4.4%) | |
| Centrally acting agents | 24 (20.0%) | 22 (17.6%) | 3 (7.1%) | 5 (11.1%) | |
| Non-specific vasodilators | 13 (10.8%) | 22 (17.6%) | 0 (0%) | 2 (4.4%) | |
| Diuretics | 16 (13.3%) | 17 (13.6%) | 6 (14.3%) | 11 (24.4%) | |
Results are shown as mean ±standard deviation, median (10th& 90th percentiles), or frequency (%), as indicated. ACEI, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker; CCB, calcium channel blocker; COPD, chronic obstructive pulmonary disease; ESA, erythropoiesis stimulating agent.
1
Hypertension defined as average pre-dialysis systolic BP > 140/90, patient taking antihypertensive medication(s), or the diagnosis of hypertension from clinical records